Efficacy Of Freeze-Dried Inactivated Rift Valley Fever Vaccine

M.H, Atwa; Abd El-Fadeel, Maha Raafat; A. Khafagy, Heba; El-Kholy, Alaa A.A.; E.Z. Kotb, Ebtsam; F. Mahmoud, Marwa Fathy

doi:10.21608/javs.2020.85571

Efficacy Of Freeze-Dried Inactivated Rift Valley Fever Vaccine

Document Type : Original Article

Authors

¹ Veterinary Serum and Vaccine Research Institute (VSVRI), Abbasia, Cairo, Egypt

² Veterinary Serum and Vaccine Research Institute (VSVRI), Abbasia, Cairo, Egypt.

³ Central Laboratory for Evaluation of Veterinary Biologics (CLEVB), ), Abbasia, Cairo, Egypt.

⁴ Professor of Veterinary Sera and Vaccines Research Institute (VSVRI), Abbassia. Egypt

⁵ Animal Reproduction Research Institute, lHarm, Giza, Egypt.

⁶ Department of Animal Reproduction Diseases, Animal Reproduction Research Institute, Al-Haram, Giza, Egypt.

10.21608/javs.2020.85571

Abstract

Rift Valley Fever (RVF) is an acute infectious zoonotic arthropod-born viral disease, affecting many species of animals and it causes great economic losses in animal wealth and has a zoonotic implication. Eradication of mosquito and vaccination is an important and best method for preventing and controlling the disease. This study was applied for the preparation and evaluation of Rift Valley Fever inactivated vaccine in a lyophilized form that is reconstituted at the time of inoculation using saponin that acts as an adjuvant. The prepared vaccine was proved to be sterile and safe. ED₅₀ Potency test of the prepared vaccine in mice gave 0.0010 ED₅₀/ML (permissible limit less than 0.02/ml). Sheep were vaccinated with 1ml S\C of the prepared lyophilized inactivated RVF vaccine and another group was vaccinated S|C with 1ml of Aluminum hydroxide inactivated RVF vaccine. The immune response of different vaccinated sheep groups was evaluated using SNT and ELISA. The Prepared lyophilized inactivated RVF vaccine gave protective NI at the second-week post-vaccination (2.1 and 0.286 OD) , then reach to peak at the 4^th week (3.28 and 0.343OD) then began to decline till ten months (1.8 and 0.241 OD), while the Aluminum hydroxide inactivated RVF vaccine gave protective NI at the second-week post-vaccination (1.7 and 0.277 OD) then reach to its NI peak at the 4^th week (3.13 and 0.312 OD) then began to decline till ten months (1.73 and 0.228 OD). From the obtained results, it was found that the prepared lyophilized inactivated RVF vaccine was safe, potent and gave approximately similar immune response as aluminum hydroxide inactivated RVF vaccine but it is better as it reduces time and effort consuming during vaccine production.

Keywords

Main Subjects

Immunology and Vaccinology

References

ABDEL GHAFFAR, S., MOHSEN, A., AYOUB, N.; EL-NIMR, M. AND FATHIA, M. 1979. Rift Valley fever in Egypt III. Diagnosis and vaccination.14th Arab. Vet. Cong., 24-29 march Cairo, page 1-11.

ABDEL-SAMEA, M. M.; ELIAN, K. AND, GIHAN, K. M. 1994. the effect of Rift Valley Fever and Sheep Pox vaccines on the immune response of sheep. J. Egypt. Vet. Med. Ass. No.2:129-136 (1994).

ALSAID , S. A., ABUL MAGD, D. M., ATWA, M. H., SOLIMAN, S. M. 2020. Evaluation of the cellular and humoral immune response of sheep vaccinated with inactivated Rift Valley Fever Vaccine Adjuvanted with Montanide gel 01^TM. Journal of Applied Veterinary Sciences, vol.5(1):22-34.

BAHNEMANN, H.G. 1990. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethyleneimine vaccine, 8: 299-303.

CENTRAL DISEASE CONTROL AND PREVENTION CDC. 2007. Ministry of Livestock and Fisheries, Rift Valley Fever information.

CENTERS DISEASE CONTROL AND PREVENTION (CDC). 2015. Rift Valley Fever.

CODE OF FEDERAL REGULATION. 2005. Animal and animal products 9, Published by the Office of the Federal Register National Archives and administration. Vet Microbial, 16(2): 101-107.

COENRAAD H., JEAN-MARC S., ARNOUD A.,, MICHAEL B.; LUKAS B., KLAUS C., ARNOLD DAAS, JOHAN DESCAMPS, ROLAND D., JULIA F., MARLIES H., MARGOT VAN DER K., ROGER L., JULIE M., DOROTHEA S., DONALD S. AND ANTONIO V. 1998. Validation Alternative Methods for the Potency Testing f Vaccines. The Report and Recommendations of ECVAM Workshop 31. ATLA, 26: 747.

EL-GABRY, G.H.; NAWAL, M.A.; HADIA A.; FATHIA, M.M. AND AYOUB, N. N. 1994. Unclassical picture of Rift valley Fever in man and animals in Aswan Governorate . Vet. Med. J; Giza. 42 (1): 135-138.

EL KARAMANY, R. M. 1981. Studies on the production of Rift Vally Fever vaccine in tissue culture. Ph. D. Thesis (Microbiology), Fac. Vet. Med., Cairo Univ.

EL-NIMR, M. M. 1980. Studies on the inactivated vaccine against Rift Valley Fever.Ph. D. Thesis (Microbiology) Fac. Vet. Assuit. Univ. Egypt

EMAN, M. S. 1995. Studies on Rift Valley Fever vaccine inactivated with Binary Ph. D. Thesis, Microbiology, Fac. of Vet. Med, Cairo Univ.

FABURAY. B.; LABEAUD, A.D.; MCVEY, D.S. AND WILLIAM, C. W. 2017. The involving transmission pattern of Rift Valley Fever in the Arabian Peninsula. amany Acad. Sci. 969: 201- 204.

FAO. 2003. Rift Valley Fever. EMPRES Transboundary Animal Disease. Bulletin, issue No. 23.

GIHAN, K. M.; ELIAN, K. A. 1997. Comparative studies on the serological response of locally produced live attenuated and inactivated Rift Valley vaccines. Egypt. Vet. Med. Ass., 57, No. 1: 949 – 957.

IMAM, I. Z. E.; M.A.; DARWISH, M.A. AND EL- KARAMANY J. R. 1979. an epidemic of Rift Valley fever in Egypt. Diagnosis Rift Valley fever in man. Bulletin of the World Health Organization. 57(3); 437.

KATHRYN, A.; HUBBARD, B. S. C.; ARTHUR BUSKERVILLE, DVSC, PH D. AND JOHN. 1991. The ability of a mutagenized virus variant to protect young lambs from Rift Valley Fever.Amer. J. Vet. Res., Vol.52: Jan , 1991.

MACPHERSON, J.A. AND STOCKER, N.G. 1962. Polyoma Transformation of hamster cell clones an investigation of hamster cell clones of genetic factors affecting all competence. Virology, 16: 147.

MAHA G. SOLIMAN1, ALY F. MOHAMED, RASHA A. EL SAYED1 AND ASMAA A. ABO ELQASEM. 2017. The immune-enhancing potential of the sphere and rod gold nanoparticles to Rift Valley Fever vaccine relative to time: in vitro study. ejbps, v.4: 529.

MARK, W. MELLENCAMP. 2004. Chemically inactivated EHV-1 kya virus; and an adjuvant which includes cross-linked olefinically unsaturated carboxylic acid polymer. Patents, publication number US 6803041 B2.

MAYR A., THEIN, P. &SCHEID, N. 1978. Immunization experiments with inactivated EHV-1. In proceeding 4thInt. Conf., Equine infect. Dis., Lyon edited by Bryans, J.T.and Gerber Vet. Pub.Inc. princtone, New Jersey, 57 .

NDEYE, S. B.; HAMPATE, B.; GAMOU F.; ELKHALIL, I.; MAMADOU, Y.; DIALLO, ABDOURAHMANE, S.; PAPE, M. S.; OUSMANE, F.; BRAHIME, MOHAMED L. S.; AND AMADOU, A. S. 2015. Detection of the Northeastern African Rift Valley Fever Virus Lineage during the 2015 Outbreak Mauritania Open Forum Infectious Diseases. 102

NEHAL, S. SALEH. 2006. Preliminary trials for the production of equine viral abortion inactivated vaccine. Ph. D. Thesis, Virology Benha Univ.

NEHAL S.SALEH, EMAN M.EBEID, FATMA F. WARDA, ASHRAF T. ELDAKHLY, NASHWA K. MADKOUR, MAHMOUD A, ELKABANY AND IBRAHEM M. A. SOLIMAN. 2017. Lyophilized EHV-1 vaccine inactivated and adjuvanted by quillaja Saponaria Molina extract. J. of Virol. Sci., Vol.1:123.

NGUKU P.M.1.; SHARIF, SK.; MUTONGA, D.; AMWAYI, S; OMOLO .J.; MOHAMMED, O.; FARNON, E.C.; GOULD.; L..H; LEDERMAN, E.; RAO, C, SANG R, SCHNABEL D, FEIKIN DR, HIGHTOWER A, NJENGA M.K.; BREIMAN, R.F. 2006. An investigation of a major outbreak of Rift Valley fever in Kenya: The American journal of tropical medicine and hygiene. 5; 83(2): 05–13.

ODA K, MATSUDA H, MURAKAMI T, KATAYAMA S, OHGITANI T, YOSHIKAWA M. 2000. Adjuvant and hemolytic activities of 47 saponins derived from medicinal and food plants. BiolChem 381:67–74.

OIE TERRESTRIAL MANUAL. 2012. RVF Chapter 2.1.15. –pp (334-343).

OIE. 2018. OIE Terrestrial manual 2018, chapter 2.1.14.

OIE TERRESTRIAL MANUAL. 2015. Rift Valley Fever, May Chapter 2.5.9.pp.1-12.

RANDALL, R.; BINN, L.N. AND HARRISON, V.R. 1964. Immunization against Rift Valley Fever. Studies on the immunogenicity of the lyophilized formalin-inactivated vaccine. J. Imm., 93(2): 293-299.

REED, L.J., AND MUENCH, H. 1938. A simple method for estimating 50 percent endpoint. Amer.J. Hyg.,27: 493.

SAMIA, A. K. 2011. Observations on rift valley fever virus and vaccines in Egypt. Virol J. 2011; 8: 532.

SAMUILENKO, A.Y.A. 1982. Dependence of immunity on the dose of adjuvant (with Saponin in FMD vaccine). Veterinary, Moscow, USSR, No. 9, 28-29, blokanbinant, shehelkov, Moskovskaya Oblast, USSR.

SELLERS, R.F.; PEDGLEY, D.E., AND TUCKER, M.R. 1982. RiftValley fever, Egypt 1977, disease spread by windborne insect vectors.

TAHA, M. M. 1982. Studies on the inactivated vaccine of Rift Valley Fever Virus.Ph. D. Thesis (Microbiology), Fac. Vet. Med., Cairo Univ.

VOLLER, A.; BIDWELL, D. AND BARTLETT, A. 1976. Microplate enzyme immunoassay for the immune-diagnosis of virus infection .Am. Soc. for Micro.,506.

WASSEL, M.S.; ABOULSAOUD, S.; GIRGIS, S.; HUSSEIN, A.Z. AND EMAN, EL-RAWY. 1996. Trials for preparation and evaluation of a combined vaccine for IBR (IBR-V),(BVD-V), (PI-3V), P. multocida, and P. haemolytica in Egypt, Assiut Vet.Med. J., 35 (70).

WHO/FAO MEETING. 1983. The use of veterinary vaccines for prevention and control of Rift Valley fever. Bulletin of the World Health Organization, 61 (2): 261.